NURIX THERAPEUTICS INC (NRIX) Stock Fundamental Analysis
USA - NASDAQ:NRIX - US67080M1036 - Common Stock
12.36 USD
+0.1 (+0.82%)
Overall NRIX gets a fundamental rating of 3 out of 10. We evaluated NRIX against 534 industry peers in the Biotechnology industry. NRIX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NRIX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NRIX has reported negative net income.
NRIX had a negative operating cash flow in the past year.
In the past 5 years NRIX always reported negative net income.
NRIX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NRIX's Return On Assets of -46.85% is in line compared to the rest of the industry. NRIX outperforms 53.00% of its industry peers.
NRIX has a Return On Equity of -65.76%. This is comparable to the rest of the industry: NRIX outperforms 58.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.85% | ||
| ROE | -65.76% | ||
| ROIC | N/A |
ROA(3y)-37.56%
ROA(5y)-29.63%
ROE(3y)-55.97%
ROE(5y)-43.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NRIX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NRIX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NRIX has been increased compared to 5 years ago.
There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.58, we must say that NRIX is in the distress zone and has some risk of bankruptcy.
NRIX's Altman-Z score of 0.58 is fine compared to the rest of the industry. NRIX outperforms 61.61% of its industry peers.
NRIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.58 |
ROIC/WACCN/A
WACC8.77%
2.3 Liquidity
A Current Ratio of 5.35 indicates that NRIX has no problem at all paying its short term obligations.
NRIX has a Current ratio (5.35) which is in line with its industry peers.
A Quick Ratio of 5.35 indicates that NRIX has no problem at all paying its short term obligations.
NRIX has a Quick ratio (5.35) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.35 | ||
| Quick Ratio | 5.35 |
3. Growth
3.1 Past
NRIX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.06%.
NRIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.32%.
Measured over the past years, NRIX shows a quite strong growth in Revenue. The Revenue has been growing by 11.88% on average per year.
EPS 1Y (TTM)-2.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.73%
Revenue 1Y (TTM)48.32%
Revenue growth 3Y22.4%
Revenue growth 5Y11.88%
Sales Q2Q%-37.29%
3.2 Future
NRIX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.87% yearly.
NRIX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.79% yearly.
EPS Next Y-13.1%
EPS Next 2Y-15.27%
EPS Next 3Y-7.38%
EPS Next 5Y6.87%
Revenue Next Year55.2%
Revenue Next 2Y-0.67%
Revenue Next 3Y8.2%
Revenue Next 5Y43.79%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NRIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NRIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NRIX's earnings are expected to decrease with -7.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.27%
EPS Next 3Y-7.38%
5. Dividend
5.1 Amount
No dividends for NRIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NRIX (11/5/2025, 3:27:02 PM)
12.36
+0.1 (+0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners112.91%
Inst Owner Change-0.52%
Ins Owners1.44%
Ins Owner Change0.66%
Market Cap950.24M
Revenue(TTM)83.69M
Net Income(TTM)-244785000
Analysts84.17
Price Target28.62 (131.55%)
Short Float %18.67%
Short Ratio11.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.03%
Min EPS beat(2)-20.05%
Max EPS beat(2)30.11%
EPS beat(4)2
Avg EPS beat(4)3.85%
Min EPS beat(4)-20.05%
Max EPS beat(4)30.11%
EPS beat(8)4
Avg EPS beat(8)-1.5%
EPS beat(12)7
Avg EPS beat(12)2.35%
EPS beat(16)8
Avg EPS beat(16)0.68%
Revenue beat(2)1
Avg Revenue beat(2)50.09%
Min Revenue beat(2)-53.76%
Max Revenue beat(2)153.94%
Revenue beat(4)3
Avg Revenue beat(4)35.94%
Min Revenue beat(4)-53.76%
Max Revenue beat(4)153.94%
Revenue beat(8)4
Avg Revenue beat(8)8.04%
Revenue beat(12)7
Avg Revenue beat(12)3.11%
Revenue beat(16)9
Avg Revenue beat(16)-0.74%
PT rev (1m)-6.48%
PT rev (3m)-6.27%
EPS NQ rev (1m)-4.59%
EPS NQ rev (3m)-7.12%
EPS NY rev (1m)-7.67%
EPS NY rev (3m)-9.02%
Revenue NQ rev (1m)-8.04%
Revenue NQ rev (3m)-1.92%
Revenue NY rev (1m)-11.07%
Revenue NY rev (3m)-7.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.35 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.55 | ||
| P/tB | 2.55 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.97
EYN/A
EPS(NY)-3.84
Fwd EYN/A
FCF(TTM)-3.14
FCFYN/A
OCF(TTM)-3
OCFYN/A
SpS1.09
BVpS4.84
TBVpS4.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.85% | ||
| ROE | -65.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-37.56%
ROA(5y)-29.63%
ROE(3y)-55.97%
ROE(5y)-43.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 287.86% | ||
| Cap/Sales | 13.12% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.35 | ||
| Quick Ratio | 5.35 | ||
| Altman-Z | 0.58 |
F-Score5
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)146.61%
Cap/Depr(5y)170.28%
Cap/Sales(3y)19.87%
Cap/Sales(5y)20.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.73%
EPS Next Y-13.1%
EPS Next 2Y-15.27%
EPS Next 3Y-7.38%
EPS Next 5Y6.87%
Revenue 1Y (TTM)48.32%
Revenue growth 3Y22.4%
Revenue growth 5Y11.88%
Sales Q2Q%-37.29%
Revenue Next Year55.2%
Revenue Next 2Y-0.67%
Revenue Next 3Y8.2%
Revenue Next 5Y43.79%
EBIT growth 1Y-37.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.68%
EBIT Next 3Y-14.17%
EBIT Next 5YN/A
FCF growth 1Y-56.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.79%
OCF growth 3YN/A
OCF growth 5YN/A
NURIX THERAPEUTICS INC / NRIX FAQ
What is the ChartMill fundamental rating of NURIX THERAPEUTICS INC (NRIX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to NRIX.
Can you provide the valuation status for NURIX THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to NURIX THERAPEUTICS INC (NRIX). This can be considered as Overvalued.
How profitable is NURIX THERAPEUTICS INC (NRIX) stock?
NURIX THERAPEUTICS INC (NRIX) has a profitability rating of 1 / 10.
How financially healthy is NURIX THERAPEUTICS INC?
The financial health rating of NURIX THERAPEUTICS INC (NRIX) is 6 / 10.